Nano-X Imaging (NASDAQ:NNOX) vs. Insulet (NASDAQ:PODD) Head-To-Head Survey

Insulet (NASDAQ:PODD) and Nano-X Imaging (NASDAQ:NNOX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Profitability

This table compares Insulet and Nano-X Imaging’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
Nano-X Imaging	-926.05%	-116.93%	-100.67%

Earnings & Valuation

This table compares Insulet and Nano-X Imaging”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71 billion	3.37	$247.10 million	$5.35	24.61
Nano-X Imaging	$13.02 million	3.84	-$75.02 million	($2.14)	-0.30

Insulet has higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Insulet has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Nano-X Imaging has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Insider and Institutional Ownership

21.5% of Nano-X Imaging shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Insulet and Nano-X Imaging, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2	11	13	0	2.42
Nano-X Imaging	1	2	2	1	2.50

Insulet presently has a consensus target price of $195.40, suggesting a potential upside of 48.38%. Nano-X Imaging has a consensus target price of $4.33, suggesting a potential upside of 581.66%. Given Nano-X Imaging’s stronger consensus rating and higher probable upside, analysts clearly believe Nano-X Imaging is more favorable than Insulet.

Summary

Insulet beats Nano-X Imaging on 9 of the 15 factors compared between the two stocks.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

About Nano-X Imaging

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.